Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Buy Rating

by · The Cerbat Gem

Wall Street Zen upgraded shares of Haemonetics (NYSE:HAE – Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday.

HAE has been the subject of a number of other reports. Barrington Research boosted their price objective on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Citigroup decreased their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price target on shares of Haemonetics in a research report on Friday, November 14th. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Haemonetics in a research note on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $79.70.

View Our Latest Analysis on HAE

Haemonetics Stock Performance

Shares of HAE stock opened at $83.98 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. The firm has a fifty day simple moving average of $61.83 and a two-hundred day simple moving average of $63.80. Haemonetics has a 12 month low of $47.31 and a 12 month high of $85.23. The firm has a market capitalization of $3.93 billion, a PE ratio of 24.56, a price-to-earnings-growth ratio of 1.51 and a beta of 0.30.

Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same period last year, the company earned $1.12 earnings per share. The business’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Analysts forecast that Haemonetics will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust raised its position in Haemonetics by 11.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after acquiring an additional 152 shares during the period. GAMMA Investing LLC increased its stake in shares of Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 165 shares during the last quarter. Quarry LP raised its holdings in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares during the period. Verdence Capital Advisors LLC lifted its stake in Haemonetics by 3.6% in the second quarter. Verdence Capital Advisors LLC now owns 6,216 shares of the medical instruments supplier’s stock valued at $464,000 after purchasing an additional 214 shares during the last quarter. Finally, Retirement Systems of Alabama grew its holdings in Haemonetics by 0.4% during the second quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock valued at $4,581,000 after purchasing an additional 256 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Featured Stories